| Management of chronic myeloid leukemia in 2023–common ground and common sense J Senapati, K Sasaki, GC Issa, JH Lipton, JP Radich, E Jabbour, ... Blood cancer journal 13 (1), 58, 2023 | 49 | 2023 |
| Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute myeloid leukemia … N Daver, J Senapati, A Maiti, S Loghavi, TM Kadia, CD DiNardo, ... Blood 140 (Supplement 1), 141-144, 2022 | 44 | 2022 |
| A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL N Jain, J Senapati, B Thakral, A Ferrajoli, P Thompson, J Burger, S Basu, ... Blood Advances 7 (10), 1958-1966, 2023 | 32 | 2023 |
| Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia J Senapati, E Jabbour, H Kantarjian, NJ Short Leukemia 37 (1), 5-17, 2023 | 31 | 2023 |
| Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute … E Jabbour, NJ Short, J Senapati, N Jain, X Huang, N Daver, CD DiNardo, ... The Lancet Haematology 10 (6), e433-e444, 2023 | 27 | 2023 |
| North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need N Pemmaraju, H Kantarjian, K Sweet, E Wang, J Senapati, NR Wilson, ... Blood 141 (6), 567-578, 2023 | 23 | 2023 |
| Diffuse large B cell lymphoma in wiskott-Aldrich syndrome: a case report and review of literature J Senapati, AJ Devasia, S David, MT Manipadam, S Nair, ... Indian Journal of Hematology and Blood Transfusion 30, 309-313, 2014 | 19 | 2014 |
| Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia J Senapati, S Urrutia, S Loghavi, NJ Short, GC Issa, A Maiti, HA Abbas, ... Blood 142 (19), 1647-1657, 2023 | 17 | 2023 |
| Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia J Senapati, M Shoukier, G Garcia‐Manero, X Wang, K Patel, T Kadia, ... American journal of hematology 97 (5), 574-582, 2022 | 11 | 2022 |
| Transfusion practices during the COVID-19 pandemic: An experience from a hematology daycare in India J Senapati, M Aggarwal, L Louis, SA Mirza, P Kumar, R Dhawan, J Dass, ... Transfusion and Apheresis Science 60 (2), 103025, 2021 | 11 | 2021 |
| Asymptomatic gastrosplenic fistula in a patient with marginal zonal lymphoma transformed to diffuse large B cell lymphoma—a case report and review of literature J Senapati, AJ Devasia, S Sudhakar, A Viswabandya Annals of hematology 93, 1599-1602, 2014 | 10 | 2014 |
| A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and … J Senapati, M Muftuoglu, J Ishizawa, HA Abbas, S Loghavi, G Borthakur, ... Blood cancer journal 13 (1), 101, 2023 | 9 | 2023 |
| Prevention and management of carbapenem-resistant Enterobacteriaceae in haematopoietic cell transplantation DSK Sahitya, A Jandiyal, A Jain, J Senapati, S Nanda, M Aggarwal, ... Therapeutic Advances in Infectious Disease 8, 20499361211053480, 2021 | 9 | 2021 |
| Tele-medicine services in hematological practice during Covid pandemic: its feasibility and difficulties P Kumar, M Aggarwal, R Dhawan, J Dass, G Kumar, V Sharma, S Mirza, ... Indian Journal of Hematology and Blood Transfusion 37, 528-533, 2021 | 9 | 2021 |
| Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia-A case report and review of literature J Senapati, AJ Devasia, A Ganapule, L George, A Viswabandya Mediterranean Journal of Hematology and Infectious Diseases 6 (1), 2014 | 9 | 2014 |
| CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights N Pemmaraju, NR Wilson, J Senapati, MP Economides, ML Guzman, ... Leukemia Research 121, 106928, 2022 | 8 | 2022 |
| Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country J Senapati, R Dhawan, M Aggarwal, P Kumar, G Kumar Vishwanathan, ... Leukemia & Lymphoma 62 (6), 1514-1517, 2021 | 8 | 2021 |
| Combined ibrutinib and venetoclax for first-line treatment of patients with chronic lymphocytic leukemia (CLL): 4-year follow-up data N Jain, MJ Keating, PA Thompson, A Ferrajoli, J Senapati, JA Burger, ... Blood 140 (Supplement 1), 234-237, 2022 | 7 | 2022 |
| A phase II study of inotuzumab ozogamicin for the treatment of measurable residual disease-positive B-cell acute lymphoblastic leukemia J Senapati, N Short, Y Alvarado, JA Burger, N Jain, M Konopleva, ... Blood 140 (Supplement 1), 3253-3255, 2022 | 7 | 2022 |
| Which FLT3 inhibitor for treatment of AML? J Senapati, TM Kadia Current treatment options in oncology 23 (3), 359-380, 2022 | 7 | 2022 |
Anup J DevasiaAssociate Professor, Dept of Clinical Hematology, Christian Medical College, Vellore, India.Verified email at cmcvellore.ac.in
